BioMarin Pharmaceutical Inc. Forecasted to Post FY2025 Earnings of $3.03 Per Share (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Stock analysts at William Blair issued their FY2025 earnings per share estimates for shares of BioMarin Pharmaceutical in a research report issued to clients and investors on Wednesday, April 24th. William Blair analyst T. Lugo expects that the biotechnology company will post earnings of $3.03 per share for the year. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $1.85 per share.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. The business had revenue of $646.21 million for the quarter, compared to analyst estimates of $639.53 million. BioMarin Pharmaceutical had a return on equity of 5.39% and a net margin of 8.31%. The firm’s revenue was up 20.2% on a year-over-year basis. During the same period last year, the company earned $0.11 EPS.

A number of other research firms have also commented on BMRN. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $110.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, April 25th. Wells Fargo & Company lifted their price target on shares of BioMarin Pharmaceutical from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. Scotiabank increased their price objective on shares of BioMarin Pharmaceutical from $83.00 to $85.00 and gave the stock a “sector perform” rating in a research report on Thursday, April 25th. Piper Sandler dropped their price objective on shares of BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Finally, Citigroup reduced their target price on shares of BioMarin Pharmaceutical from $94.00 to $91.00 and set a “neutral” rating for the company in a research note on Thursday, April 25th. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $107.50.

BioMarin Pharmaceutical Stock Performance

BMRN stock opened at $80.76 on Monday. BioMarin Pharmaceutical has a 1-year low of $76.02 and a 1-year high of $99.56. The company has a current ratio of 2.51, a quick ratio of 1.57 and a debt-to-equity ratio of 0.12. The firm has a market cap of $15.24 billion, a PE ratio of 75.48, a P/E/G ratio of 1.36 and a beta of 0.31. The business’s 50-day moving average price is $87.29 and its two-hundred day moving average price is $89.07.

Insider Buying and Selling at BioMarin Pharmaceutical

In related news, CAO Erin Burkhart sold 2,286 shares of the business’s stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $90.00, for a total value of $205,740.00. Following the completion of the sale, the chief accounting officer now directly owns 16,156 shares in the company, valued at approximately $1,454,040. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Jean Jacques Bienaime sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $88.28, for a total transaction of $1,324,200.00. Following the completion of the sale, the director now owns 419,602 shares of the company’s stock, valued at approximately $37,042,464.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Erin Burkhart sold 2,286 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $90.00, for a total transaction of $205,740.00. Following the completion of the transaction, the chief accounting officer now directly owns 16,156 shares in the company, valued at $1,454,040. The disclosure for this sale can be found here. Insiders sold 103,229 shares of company stock valued at $9,062,967 in the last quarter. 1.85% of the stock is currently owned by insiders.

Institutional Trading of BioMarin Pharmaceutical

Several institutional investors and hedge funds have recently modified their holdings of BMRN. CWM LLC boosted its stake in shares of BioMarin Pharmaceutical by 10.0% in the 3rd quarter. CWM LLC now owns 1,301 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 118 shares in the last quarter. Handelsbanken Fonder AB raised its stake in shares of BioMarin Pharmaceutical by 1.8% during the third quarter. Handelsbanken Fonder AB now owns 91,755 shares of the biotechnology company’s stock valued at $8,118,000 after acquiring an additional 1,593 shares during the last quarter. Simplicity Solutions LLC increased its holdings in BioMarin Pharmaceutical by 8.4% in the third quarter. Simplicity Solutions LLC now owns 2,971 shares of the biotechnology company’s stock valued at $263,000 after purchasing an additional 229 shares during the period. AMI Asset Management Corp acquired a new position in BioMarin Pharmaceutical during the 3rd quarter worth about $27,838,000. Finally, Commonwealth Equity Services LLC grew its position in shares of BioMarin Pharmaceutical by 8.3% in the 3rd quarter. Commonwealth Equity Services LLC now owns 7,413 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 568 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.